Security record · archived quarter
IRWD
Ironwood Pharmaceuticals, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
1Tracked holders
0Δ holders
214.09KShares held
$777,154Reported value
+0New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 214.09K | $777,154 | n/a | n/a |
| Q2 2026 | 88 | -4 | 110.50M | $465.13M | +4 | −8 |
| Q1 2026 | 94 | +9 | 125.58M | $394.14M | +11 | −2 |
| Q4 2025 | 85 | +2 | 100.81M | $339.86M | +2 | n/a |
| Q3 2025 | 17 | 0 | 58.02M | $76.00M | n/a | n/a |
| Q2 2025 | 14 | 0 | 58.90M | $42.25M | +1 | −1 |
| Q1 2025 | 11 | 0 | 30.28M | $44.51M | +1 | −1 |
| Q4 2024 | 11 | 0 | 26.27M | $116.38M | +1 | −1 |
| Q3 2024 | 10 | -2 | 15.74M | $64.83M | n/a | −2 |
| Q2 2024 | 12 | n/a | 17.55M | $114.44M | n/a | n/a |
Who holds it · Q3 2026
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 214.09K | -2.4% | $777,154 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 222 holders, 159.91M shares, $533.78M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Aug 14
SC 13G/A: ARMISTICE CAPITAL, LLC
Aug 07
SC 13G: STATE STREET CORP
Jul 28
SC 13G/A: BlackRock, Inc.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2026 ·
Methodology ·
Get this via the API